12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Company News  |  Deals

ImevaX, ProJect Pharmaceutics deal

ProJect and ImevaX partnered to develop a formulation of ImevaX's IMX101 vaccine against Helicobacter pylori infection. The partners will use ProJect's predictive formulation analytics...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >